Aurobindo Pharma has strengthened its presence in the lucrative US generics market after receiving final approval from the US Food and Drug Administration (USFDA) for Tofacitinib tablets in 5 mg and 10 mg strengths, opening the door to a market worth nearly $500 million annually.
The approval allows the company to manufacture and market a generic version of Xeljanz, a widely prescribed treatment for rheumatoid arthritis and other autoimmune disorders.
Entry into a high-value therapy segment
The approved product is bioequivalent and therapeutically equivalent to Xeljanz tablets, marketed by PF Prism C.V., enabling Aurobindo Pharma to compete in a sizeable specialty pharmaceuticals segment.
According to IQVIA MAT data for the 12 months ended April 2026, the US market for Tofacitinib tablets is estimated at approximately $494 million, making it one of the more attractive opportunities within the oral autoimmune therapy space.
The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of Aurobindo Pharma, and the company said commercial launch activities will commence immediately.
Expanding US generics footprint
The latest approval further deepens Aurobindo Pharma’s presence in the world’s largest pharmaceutical market.
With this clearance, the company now holds a total of 586 abbreviated new drug application (ANDA) approvals from the USFDA, comprising 561 final approvals and 25 tentative approvals.
The growing portfolio underscores Aurobindo’s strategy of steadily expanding its product basket across therapeutic categories while leveraging its manufacturing capabilities to address high-value generic opportunities.
Addressing chronic disease treatment needs
Tofacitinib is prescribed for the treatment of adults with moderately to severely active rheumatoid arthritis who have shown an inadequate response or intolerance to methotrexate.
The medicine is also indicated for patients with active psoriatic arthritis who have not responded adequately to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
In addition, the therapy is approved for adults suffering from moderately to severely active ulcerative colitis who have had an inadequate response to, or are intolerant of, TNF blocker treatments.
Boost for US business
The approval comes at a time when Indian pharmaceutical companies continue to focus on complex and specialty generic products to drive growth in the US market amid pricing pressure in traditional generic segments.
For Aurobindo Pharma, the immediate launch of Tofacitinib tablets provides access to a significant revenue opportunity while further strengthening its portfolio of treatments for chronic and autoimmune diseases.
The approval also highlights the company’s continued execution in securing regulatory clearances for products with meaningful market potential in the United States.